PMID: 9556192Apr 29, 1998Paper

Clinical uroselectivity of alfuzosin in the treatment of benign prostatic hyperplasia

European Urology
R S Kirby

Abstract

The efficacy of alfuzosin in improving lower urinary tract symptoms and relieving bladder outlet obstruction has been demonstrated in numerous short- and long-term placebo-controlled studies and large-scale open studies, involving over 16,000 patients with symptomatic benign prostatic hyperplasia (BPH). Treatment with sustained release alfuzosin (5 mg twice daily) for 3 months resulted in a 5-point reduction in the International Prostate Symptom Score and a 29% increase in urinary flow rate. The benefits of alfuzosin have been confirmed in general practice. A 1-year prospective study of 5,849 men with clinical BPH treated with alfuzosin showed a 51% reduction in mean total symptom score, with a 56% decrease in mean irritative symptoms. Improvement in health-related quality of life of 3 years' duration have been recorded, including a reduction in the frequency of both diurnal and nocturnal micturition. Alfuzosin has a good safety profile. Unlike most other alpha1-blockers, a low risk of first-dose effect is seen, conveniently eliminating the necessity of dose titration at initiation of therapy. Postural symptoms related to orthostatic hypotension (a common side-effect of alpha1-blockers) are infrequent, including in the elderly ...Continue Reading

Citations

Feb 24, 2006·International Journal of Clinical Practice·L KuritzkyR Sadovsky
Feb 17, 2000·The Annals of Pharmacotherapy·M Lee
Mar 31, 2007·Naunyn-Schmiedeberg's Archives of Pharmacology·Rana Altan-YayciogluYonca A Akova
Nov 2, 2002·BJU International·H Schulte-BauklohH H Knispel
Dec 17, 2008·International Journal of Impotence Research·B-H ChungS-J Yoo
May 20, 2016·Investigative and Clinical Urology·Jin Wook KimKyung Do Kim
Jan 13, 2006·The Journal of Urology·Kevin T McVary
Jun 3, 2009·Ophthalmic Surgery, Lasers & Imaging : the Official Journal of the International Society for Imaging in the Eye·Rana Altan-YayciogluAhmet Akman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Brain Barrier

The blood brain barrier is a border that separates blood from cerebrospinal fluid. Discover the latest search on this highly selective semipermeable membrane here.

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.

Blood Brain Barrier Chips

The blood brain barrier (BBB) is comprised of endothelial cells that regulate the influx and outflux of plasma concentrations. Lab-on-a-chip devices allow scientists to model diseases and mechanisms such as the passage of therapeutic antibodies across the BBB. Discover the latest research on BBB chips here.

Blood Brain Barrier Regulation in Health & Disease

The blood brain barrier is essential in regulating the movement of molecules and substances in and out of the brain. Disruption to the blood brain barrier and changes in permeability allow pathogens and inflammatory molecules to cross the barrier and may play a part in the pathogenesis of neurodegenerative disorders. Here is the latest research in this field.